PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study.

Carlo PiccinniIppazio Cosimo AntonazzoAldo P MaggioniAntonella PedriniSilvia CalabriaGiulia RonconiLetizia DondiNello MartiniGiuseppe RobertoTiziana SampietroFrancesco SbranaBeatrice Dal PinoFederico BigazziGiuseppa Lo SurdoElisabetta VolpiStefania BiaginiRosa Gini

Published in: Clinical drug investigation (2020)

During the first year of availability, the rate of prescription of PCSK9 inhibitors appears below expectations. Patients were mainly in secondary prevention and had been slightly persistent to previous LLTs. During follow-up, the PCSK9 inhibitor monotherapy showed high levels of adherence and persistence. This real-world study sets the stage for future longer-term investigations useful to improve our knowledge on the appropriateness, drug access and public healthcare sustainability of PCSK9 inhibitors.

Keyphrases

healthcare
end stage renal disease
chronic kidney disease
ejection fraction
prognostic factors
preterm infants
metabolic syndrome
type diabetes
adipose tissue
patient reported
social media
low density lipoprotein
adverse drug